Biogen Inc.
Capitalizzazione di mercato
$30.9B
Posizione mondiale
#301
Massimo storico
$50.1B
2014-12-31
Crescita totale
+0%
dal 2026
Market Cap Context
- Larger than 18% of the 367 companies we track (globally).
- Equivalent to 0.1% of United States's GDP (2025 data).
- Just above: #300 Crown Castle Inc. ($31.7B)
- Just below: #302 Copart, Inc. ($30.5B)
- Best year: 1995 (+818%). Worst year: 2002 (-52%).
Biogen Inc. Financial Breakdown (FY 2025)
Source: Yahoo Finance — BIIB annual filings (2025) →$9.9B revenue · $2.5B operating income · $1.3B net income
- ●Operating margin: 25.0% on $9.9B in revenue.
- ●R&D is 18.0% of revenue ($1.8B).
- ●Net income margin: 13.1% — $1.3B in profit.
- ●Free cash flow: $2.0B (19.9% of revenue).
Cost / Operating Expenses
Total operating expenses $7.4B
Total
$6.6B
Capital Expenditures
$0.2B
This fiscal year (near-total AI infrastructure buildout)
Free Cash Flow
$2.0B
Trailing twelve months
Figures rounded from the annual SEC filing. Unaudited. For informational purposes only, not investment advice.
Informazioni su Biogen Inc.
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia ; tofersen (Qalsody) for the treatment of ALS; and dimethyl fumarate (Fumaderm) for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
Storico della capitalizzazione di mercato di Biogen Inc. (2026–2026)
Biogen Inc. vs Sector Peers by Market Cap
Confronta Biogen Inc.
Storico della classifica
| Anno | Capitalizzazione di mercato | Posizione | Variazione su base annua |
|---|---|---|---|
| 2026 | $30.9B | #301(↑13) | +18.9% |
| 2025 | $26.0B | #314(↑6) | +15.1% |
| 2024 | $22.6B | #320(↓59) | -40.9% |
| 2023 | $38.2B | #261(↓48) | -6.6% |
| 2022 | $40.9B | #213(↑55) | +15.4% |
| 2021 | $35.4B | #268(↓45) | -2.0% |
| 2020 | $36.2B | #223(↓57) | -17.5% |
| 2019 | $43.8B | #166(↓45) | -1.4% |
| 2018 | $44.4B | #121(↓1) | -5.5% |
| 2017 | $47.0B | #120(↓13) | +12.3% |
| 2016 | $41.9B | #107(↓19) | -7.4% |
| 2015 | $45.2B | #88(↓16) | -9.8% |
| 2014 | $50.1B | #72(↑2) | +21.4% |
| 2013 | $41.3B | #74(↑50) | +91.0% |
| 2012 | $21.6B | #124(↑4) | +33.0% |
| 2011 | $16.2B | #128(↑71) | +64.1% |
| 2010 | $9.9B | #199(↑2) | +25.3% |
| 2009 | $7.9B | #201(↓24) | +12.3% |
| 2008 | $7.0B | #177(↑21) | -16.3% |
| 2007 | $8.4B | #198(↑7) | +15.7% |
| 2006 | $7.3B | #205(↓14) | +8.6% |
| 2005 | $6.7B | #191(↓62) | -32.0% |
| 2004 | $9.8B | #129(↑40) | +81.5% |
| 2003 | $5.4B | #169(↓21) | +10.6% |
| 2002 | $4.9B | #148(↓55) | -51.9% |
| 2001 | $10.2B | #93(↑10) | +9.1% |
| 2000 | $9.3B | #103(↑9) | +92.9% |
| 1999 | $4.8B | #112(↑48) | +318.1% |
| 1998 | $1.2B | #160(↑4) | +36.7% |
| 1997 | $845.8M | #164(↓5) | +44.7% |
| 1996 | $584.4M | #159(↓10) | +21.8% |
| 1995 | $479.8M | #149(↓6) | +817.6% |
| 1994 | $52.3M | #143 |
Altre aziende del settore Sanità
Domande frequenti
What is Biogen Inc.'s market cap?
Biogen Inc. (BIIB) has a market capitalization of $30.9B, making it the #301 largest company in the world by market cap.
What was Biogen Inc.'s highest market cap?
Biogen Inc.'s all-time high market cap was $50.1B, reached in 2014-12-31. Its highest rank was #72 in 2014.
What sector is Biogen Inc. in?
Biogen Inc. is in the Healthcare sector, specifically the Drug Manufacturers - General industry. It is based in United States.
How has Biogen Inc.'s market cap changed over time?
Biogen Inc. has been tracked since 2026. Its market cap has grown by 0% from $30.9B in 2026 to $30.9B today.